Search results for: Health Policy and Regulation
Filter search results
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
…and the US on the one hand, and the EU on the other, have been the subject of many articles and commentaries [a,b,g]. To understand how this problem could be…
Compared to what? How the choice of comparator affects new medicines
14 September 2026
…the area, the short-term access versus long-term innovation incentives trade-off needs to be explicitly balanced by policy makers. Health Gain Headroom The comparator and its choice can also determine the health gains…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
…European Commission mandate. Capability: Robust methods to quantify the wider health benefits of antimicrobials (dynamic transmission and risk models; The National Institute for Health and Care Excellence (NICE) and National Health…
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?
1 July 2021
…vaccines to middle and low income countries; and price determination that is not value-driven. We argue for a demand-side approach. By pooling commitments and pre-agreeing vaccination priorities, countries avoid destructive…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…Prescriptive Model for Health, Safety, and Consumption Decisions”. Consequently, this complementarity between health and consumption is a necessary condition for reconciling ACEA and MCDA. The MCDA multi-attribute utility function value…
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
…our society and the role of health and social care within it, and surely merits a case for change. Related research Cubi-Molla, P., Buxton, M. and Devlin, N., 2021. Allocating…
‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum
24 February 2021
…their technologies, drugs and therapeutic indications, prevention and public health interventions, and other health policies, balancing health results with the costs they entail for the SNHS and for society as…
Around the World in HTAs: Zimbabwe – Seizing a window of opportunity
24 September 2026
…remains low. Many policymakers and stakeholders are unfamiliar with what HTA entails and the value it could bring to healthcare decision-making. Building understanding and buy-in will be essential for successful…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006. Available at: https://health.ec.europa.eu/system/files/2023-04/com_2023_193_1_act_en.pdf [Accessed 4 May 2023]. European Federation of Pharmaceutical…